$5.03 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter
Wall Street brokerages expect that TherapeuticsMD Inc (NASDAQ:TXMD) will report sales of $5.03 million for the current quarter, Zacks reports. Five analysts have made estimates for TherapeuticsMD’s earnings, with the highest sales estimate coming in at $6.10 million and the lowest estimate coming in at $4.34 million. TherapeuticsMD reported sales of $5.54 million in the same quarter last year, which would suggest a negative year over year growth rate of 9.2%. The company is expected to report its next earnings results on Thursday, November 2nd.
On average, analysts expect that TherapeuticsMD will report full year sales of $5.03 million for the current year, with estimates ranging from $16.70 million to $20.55 million. For the next financial year, analysts forecast that the company will report sales of $40.33 million per share, with estimates ranging from $37.63 million to $42.06 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for TherapeuticsMD.
TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The firm had revenue of $4.25 million for the quarter, compared to analyst estimates of $4.91 million. During the same quarter last year, the firm posted ($0.11) EPS. The business’s revenue was down 3.4% on a year-over-year basis.
A number of research firms have recently issued reports on TXMD. Morgan Stanley began coverage on TherapeuticsMD in a report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 target price on the stock. Jefferies Group LLC reissued a “buy” rating and issued a $15.00 target price on shares of TherapeuticsMD in a report on Friday, September 8th. Deutsche Bank AG reissued a “buy” rating and issued a $10.00 target price on shares of TherapeuticsMD in a report on Wednesday, September 13th. Oppenheimer Holdings, Inc. set a $10.00 target price on TherapeuticsMD and gave the company a “buy” rating in a report on Thursday, August 17th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $20.00 target price on shares of TherapeuticsMD in a report on Monday, August 21st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $14.88.
In other TherapeuticsMD news, Director Tommy G. Thompson acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were purchased at an average price of $5.99 per share, with a total value of $29,950.00. Following the completion of the acquisition, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Hedge funds have recently made changes to their positions in the stock. Carl Domino Inc purchased a new stake in TherapeuticsMD during the second quarter worth $235,000. Raymond James Financial Services Advisors Inc. boosted its position in TherapeuticsMD by 56.1% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock worth $207,000 after purchasing an additional 10,330 shares in the last quarter. Stifel Financial Corp boosted its position in TherapeuticsMD by 125.4% during the first quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock worth $3,091,000 after purchasing an additional 238,885 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in TherapeuticsMD by 94.5% during the first quarter. Oppenheimer & Co. Inc. now owns 41,466 shares of the company’s stock worth $298,000 after purchasing an additional 20,148 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in TherapeuticsMD by 45.9% during the first quarter. Point72 Asset Management L.P. now owns 296,700 shares of the company’s stock worth $2,136,000 after purchasing an additional 93,400 shares in the last quarter.
Shares of TherapeuticsMD (NASDAQ:TXMD) traded down 0.682% on Thursday, hitting $5.095. The stock had a trading volume of 1,726,645 shares. The firm has a 50 day moving average of $6.04 and a 200 day moving average of $5.49. The stock’s market cap is $1.04 billion. TherapeuticsMD has a 12 month low of $3.50 and a 12 month high of $8.30.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.